Anti-PD-1 treatment improves antitumour immune responses in patients with colorectal cancer, melanoma, renal cell carcinoma, non-small cell lung cancer, haematologic malignancies, and bladder cancer, resulting from its ability to transform anergic T cells into functional T cells [6,7,8]. Here, PDCD1 is linked to melanoma.